论文部分内容阅读
对32例口腔癌患者治疗前后血清白细胞介素2（IL－2）水平进行监测，结果发现：口腔癌患者治疗前血清IL-2水平显著低于正常人（P＜0．01），且血清IL-2水平与肿瘤临床分期有关；治疗后血清IL－2水平呈明显回升，与治疗前相比有显著性差异（P＜0．01）。研究结果提示：口腔癌患者血清IL－2含量能反应机体抗肿瘤免疫水平的高低，可作为评价病情严重程度及治疗效果的一个客观指标。
The serum interleukin-2 (IL-2) levels were monitored before and after treatment in 32 patients with oral cancer. The results showed that the serum IL-2 levels in patients with oral cancer before treatment were significantly lower than those in normal subjects (P<0.01). The level of IL-2 was related to the clinical stage of the tumor; serum IL-2 levels after treatment significantly increased, which was significantly different from that before treatment (P<0.01). The results suggest that serum IL-2 levels in patients with oral cancer can reflect the body’s level of anti-tumor immunity, and can be used as an objective index to evaluate the severity of the disease and the treatment effect.